Search

Your search keyword '"Kumada, Hiromitsu"' showing total 2,379 results
Start Over Author "Kumada, Hiromitsu"
2,379 results on '"Kumada, Hiromitsu"'

161. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

Author

Kumada, Hiromitsu, Suzuki, Yoshiyuki, Ikeda, Kenji, Toyota, Joji, Karino, Yoshiyasu, Chayama, Kazuaki, Kawakami, Yoshiiku, Ido, Akio, Yamamoto, Kazuhide, Takaguchi, Koichi, Izumi, Namiki, Koike, Kazuhiko, Takehara, Tetsuo, Kawada, Norifumi, Sata, Michio, Miyagoshi, Hidetaka, Eley, Timothy, McPhee, Fiona, Damokosh, Andrew, Ishikawa, Hiroki, and Hughes, Eric

Published
2014
Full Text
View/download PDF

165. Antiviral activity, dose–response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial

Author

Shindo, Michiko, Chayama, Kazuaki, Mochida, Satoshi, Toyota, Joji, Tomita, Eiichi, Kumada, Hiromitsu, Yokosuka, Osamu, Sata, Michio, Hayashi, Norio, Suzuki, Kazuyuki, Okanoue, Takeshi, Tsubouchi, Hirohito, Ishikawa, Hiroki, Seriu, Taku, and Omata, Masao

Published
2009
Full Text
View/download PDF

170. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B

Author

Kobashi, Haruhiko, Fujioka, Shin-ichi, Kawaguchi, Mitsuhiko, Kumada, Hiromitsu, Yokosuka, Osamu, Hayashi, Norio, Suzuki, Kazuyuki, Okanoue, Takeshi, Sata, Michio, Tsubouchi, Hirohito, Sato, Chifumi, Kiyosawa, Kendo, Tanikawa, Kyuichi, Seriu, Taku, Ishikawa, Hiroki, Takaki, Akinobu, Iwasaki, Yoshiaki, Osawa, Toshiya, Takaki, Toshiyuki, Sakaguchi, Kosaku, Shiratori, Yasushi, Yamamoto, Kazuhide, Tenney, Daniel J., and Omata, Masao

Published
2009
Full Text
View/download PDF

175. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma.

Author

Kawamura, Yusuke, Kobayashi, Masahiro, Shindoh, Junichi, Matsumura, Masaru, Okubo, Satoshi, Muraishi, Nozomu, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, and Kumada, Hiromitsu

Subjects
THERAPEUTIC use of monoclonal antibodies, THERAPEUTIC use of antineoplastic agents, PREOPERATIVE care, DISEASE progression, CONFIDENCE intervals, MULTIVARIATE analysis, TREATMENT effectiveness, PROTEIN-tyrosine kinase inhibitors, RADIOPHARMACEUTICALS, POSITRON emission tomography, SURVIVAL analysis (Biometry), DEOXY sugars, BEVACIZUMAB, PROGRESSION-free survival, HEPATOCELLULAR carcinoma
Abstract

Background and Aims: The aim of this study was to identify the utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) as a predictor of early progressive disease (e-PD) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atezo/Bev). Methods: Twenty consecutive patients with measurable intrahepatic target nodules who received Atezo/Bev treatment were reviewed. The oncological aggressiveness of tumors estimated by 18F-FDG-PET/CT was analyzed using the rate of e-PD within 12 weeks and early progression-free survival (e-PFS) and overall survival (OS). Multivariate analysis was used to identify potential confounders for PD during Atezo/Bev therapy. Results: Using the Response Evaluation Criteria in Solid Tumors version 1.1, a tumor-to-normal liver ratio (TLR) ≥2, indicating higher oncological aggressiveness in HCCs, was associated with lower objective response rates compared with TLR values <2 (18% vs. 33%, respectively). Moreover, TLR values ≥2 were significantly associated with higher e-PD rates compared with TLR values <2 (64% vs. 11%, respectively) and worse e-PFS (p = 0.021). In multivariate analysis, TLR ≥2 showed marginal significance as a predictor of e-PD (p = 0.053), and utility as a predictor for worse e-PFS (hazard ratio, 7.153; 95% confidence interval, 1.258–40.689; p = 0.027). In contrast, no significant differences in OS with/without e-PD were observed during the treatment course. In this study, 8 patients experienced e-PD and almost 40% of patients experienced acceptable disease control following subsequent lenvatinib treatment. Conclusion: Pretreatment 18F-FDG-PET/CT may be a useful new predictor of e-PD and may enable early decision-making based on early treatment changes following Atezo/Bev treatment of HCC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

176. Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance

Author

Suzuki, Fumitaka, primary, Hosaka, Tetsuya, additional, Imaizumi, Masayasu, additional, Kobayashi, Mariko, additional, Ohue, Chiharu, additional, Suzuki, Yoshiyuki, additional, Fujiyama, Shunichiro, additional, Kawamura, Yusuke, additional, Sezaki, Hitomi, additional, Akuta, Norio, additional, Kobayashi, Masahiro, additional, Saitoh, Satoshi, additional, Arase, Yasuji, additional, Ikeda, Kenji, additional, and Kumada, Hiromitsu, additional

Published
2021
Full Text
View/download PDF

177. Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir

Author

Suzuki, Fumitaka, primary, Sezaki, Hitomi, additional, Hosaka, Tetsuya, additional, Suzuki, Yoshiyuki, additional, Fujiyama, Shunichiro, additional, Kawamura, Yusuke, additional, Akuta, Norio, additional, Kobayashi, Masahiro, additional, Saitoh, Satoshi, additional, Arase, Yasuji, additional, Ikeda, Kenji, additional, Kobayashi, Mariko, additional, Mineta, Rie, additional, Suzuki, Yukiko, additional, and Kumada, Hiromitsu, additional

Published
2021
Full Text
View/download PDF

178. Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib

Author

Kasuya, Kayoko, primary, Kawamura, Yusuke, additional, Kobayashi, Masahiro, additional, Shindoh, Junichi, additional, Kobayashi, Yuta, additional, Kajiwara, Akira, additional, Iritani, Soichi, additional, Fujiyama, Shunichiro, additional, Hosaka, Tetsuya, additional, Saitoh, Satoshi, additional, Sezaki, Hitomi, additional, Akuta, Norio, additional, Suzuki, Fumitaka, additional, Suzuki, Yoshiyuki, additional, Ikeda, Kenji, additional, Arase, Yasuji, additional, Eguchi, Yuichiro, additional, Hashimoto, Masaji, additional, and Kumada, Hiromitsu, additional

Published
2021
Full Text
View/download PDF

181. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment

Author

Kawamura, Yusuke, primary, Kobayashi, Masahiro, additional, Shindoh, Junichi, additional, Kobayashi, Yuta, additional, Okubo, Satoshi, additional, Muraishi, Nozomu, additional, Iritani, Soichi, additional, Fujiyama, Shunichiro, additional, Hosaka, Tetsuya, additional, Saitoh, Satoshi, additional, Sezaki, Hitomi, additional, Akuta, Norio, additional, Suzuki, Fumitaka, additional, Suzuki, Yoshiyuki, additional, Ikeda, Kenji, additional, Arase, Yasuji, additional, Hashimoto, Masaji, additional, and Kumada, Hiromitsu, additional

Published
2021
Full Text
View/download PDF

182. A Blood-Based Prognostic Liver Secretome Signature and Long-Term Hepatocellular Carcinoma Risk in Advanced Liver Fibrosis

Author

Fujiwara, Naoto, primary, Kobayashi, Masahiro, additional, Fobar, Austin J., additional, Hoshida, Ayaka, additional, Marquez, Cesia A., additional, Koneru, Bhuvaneswari, additional, Panda, Gayatri, additional, Taguri, Masataka, additional, Qiang, Tongqi, additional, Raman, Indu, additional, Li, Quan-Zhen, additional, Hoshida, Hiroki, additional, Sezaki, Hitomi, additional, Kumada, Hiromitsu, additional, Tateishi, Ryosuke, additional, Yokoo, Takeshi, additional, Yopp, Adam C., additional, Chung, Raymond T., additional, Fuchs, Bryan C., additional, Baumert, Thomas F., additional, Marrero, Jorge A., additional, Parikh, Neehar D., additional, Zhu, Shijia, additional, Singal, Amit, additional, and Hoshida, Yujin, additional

Published
2021
Full Text
View/download PDF

185. Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease

Author

Arase, Yasuji, Kawamura, Yusuke, Seko, Yuya, Kobayashi, Mariko, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Akuta, Norio, Kobayashi, Masahiro, Sezaki, Hitomi, Saito, Satoshi, Hosaka, Tetsuya, Ikeda, Kenji, Kumada, Hiromitsu, Ohmoto-Sekine, Yuki, Hsieh, Shiun Dong, Amakawa, Kazuhisa, Ogawa, Kyoko, Matsumoto, Naoki, Iwao, Akiko, Tsuji, Hiroshi, Hara, Shigeko, Mori, Yasumichi, Okubo, Minoru, Sone, Hirohito, and Kobayashi, Tetsuro

Published
2013
Full Text
View/download PDF

187. Gene expression in fixed tissues and outcome in hepatocellular carcinoma

Author

Hoshida, Yujin, Villanueva, Augusto, Kobayashi, Masahiro, Peix, Judi, Chiang, Derek Y., Camargo, Amy, Gupta, Supriya, Wrobel, Matthew J., Moore, Jamie, Lerner, Jim, Reich, Michael, Chan, Jennifer A., Glickman, Jonathan N., Ikeda, Kenji, Masaji Hashimoto, Watanabe, Goro, Daidone, Maria G., Roayale, Sasan, Schwartz, Myron, Thung, Swan, Salvesen, Helga B., Gabriel, Stacey, Mazzaferro, Vincenzo, Bruix, Jordi, Friedman, Scott L., Kumada, Hiromitsu, Llovet, Josep M., and Golub, Todd R.

Subjects
Hepatoma -- Diagnosis, Hepatoma -- Risk factors, Hepatoma -- Causes of, Gene expression -- Analysis
Abstract

The study aims to establish the use of gene expression profiling in fixed tissue as an effective means of predicting the outcome of hepatocellular carcinoma. The results confirm the feasibility of genomewise expression profiling of fixed tissues in influencing the outcome of hepatocellular carcinoma.

Published
2008

191. Abstracts of selected papers presented at the 33rd Annual Meeting of the Japanese Society of Gastroenterology

Author

Hasuo, Tomonobu, Hosoi, Tohzo, Nagano, M., Motizuki, F., Arima, Miwako, Kouzu, Teruo, Murata, Yoko, Ide, Hiroko, Shiozaki, Hitoshi, Kobayashi, Kenji, Kawano, Tatsuyuki, Endo, Mitsuo, Koyama, Shohei, Tsujii, Hirohiko, Kondo, Fukuo, Ebara, Masaaki, Nakashima, Osamu, Kojiro, Masamichi, Takayama, Tadatoshi, Makuuchi, Masatoshi, Kurokawa, Fumie, Okita, Kiwamu, Itoh, Yoshinobu, Akamatsu, Kouichi, Tanaka, Sachiko, Kitamura, Tsugio, Ikeda, Kenji, Kumada, Hiromitsu, Majima, Yasuo, Tanikawa, Kyuichi, Imaoka, Shingi, Sasaki, Yo, Ohkura, Yasuo, Nakamura, Kyoichi, Hirakawa, Masahiko, Fuchigami, Tadahiko, Tsuda, Sumio, Matsui, Toshiyuki, Tsuruta, Osamu, Arima, Nobuyuki, Ohishi, Takashi, Egawa, Naoto, Sawada, Toshio, Muto, Tetsuichiro, Sata, Michio, Tanikawa, Kyuichi, Takase, Shujiro, Tsutsumi, Mikihiro, Uchikoshi, Toshiyuki, Maeyama, Shiro, Unoura, M., Kaneko, S., Kiyosawa, Kendo, Tanaka, Eiji, Nishiguchi, Shuhei, Kuroki, Tetsuo, Hosoda, Ito, Yoshimi, Yasuda, Kiyomi, Tashima, Koichi, Ohta, Yasuyuki, Okazaki, Yukinori, Miyoshi, Yasuhiko, Yoshino, Junji, Nakazawa, Saburo, Ashida, Kiyoshi, Sakaguchi, Masahiro, Ohara, Shuichi, Asaki, Shigeru, Ise, Hideo, Matsuno, Seiki, Higashide, Shun-ichi, Inoue, Kazutomo, Matsumoto, Teiji, Tsunoda, Tsukasa, Moriizumi, S., Shimosegawa, T., Sawabu, Norio, Satomura, Yoshitake, Noda, Aiji, Ibuki, Eri, Atsumi, M., Kashima, K., Omagari, Kazuhiro, Toyonaga, Atsushi, Takasaki, Yoshihisa, Muranaga, Tomoko, Tada, Masahiro, Murakami, Atsushi, Kihira, Ken, Yosida, Yukio, Kimura, Ken, Miyazaki, Yasuhiro, Hirao, Masanori, Inoue, Kazuhiko, Hidaka, Tohru, Inoue, Osami, Yatsuhashi, Hiroshi, Kaminishi, Michio, Shimoyama, Shouji, Takahashi, Michiko, Yamada, Gotaro, Takano, Susumu, Omata, Masao, Ito, Nobuyasu, Tameda, Yukihiko, Kondo, T., Sainokami, S., Arase, Yasuji, Kumada, Hiromitsu, Seki, Takeshi, Kiyosawa, Kendo, Yasunaga, Mitsuru, Sanuki, Kazutosi, Tomiya, Tomoaki, Fujiwara, Kenji, Tada, Kouji, Akamatsu, Kouichi, Ohtake, Yoshio, Hirasawa, Hiroyuki, Suzuki, Kazuyuki, Sato, Shunichi, Takahashi, Hiroaki, Mizumoto, Ryuji, Aoike, Akira, Watanabe, Kazuhiko, Yamaguti, Osahumi, Kuwayama, Hajime, Asakura, Hitoshi, Narisawa, Rintaro, Kumashiro, Ryukichi, Sata, Michio, Kubota, Yoshitsugu, Inoue, Kyoichi, Shibata, Tokimune, Hayakawa, Tetsuo, and Hattori, Takanori

Published
1993
Full Text
View/download PDF

194. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C

Author

Omata, Masao, Yoshida, Haruhiko, Toyota, Joji, Tomita, Eiichi, Nishiguchi, Shuhei, Hayashi, Norio, Iino, Shiro, Makino, Isao, Okita, Kiwamu, Toda, Gotaro, Tanikawa, Kyuichi, and Kumada, Hiromitsu

Subjects
Chronic active hepatitis -- Drug therapy, Hepatitis C -- Drug therapy, Ursodiol -- Dosage and administration, Ursodiol -- Research, Drug therapy -- Patient outcomes, Drug therapy -- Research, Health
Published
2007

196. (18)F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib

Author

Kawamura, Yusuke, Kobayashi, Masahiro, Shindoh, Junichi, Kobayashi, Yuta, Kasuya, Kayoko, Sano, Tomoya, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, and Kumada, Hiromitsu

Subjects
Original Paper
Abstract

BACKGROUND AND AIMS: This study aimed to identify the utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) as a predictor of the response of hepatocellular carcinoma (HCC) to lenvatinib. METHODS: We evaluated 28 consecutive patients with HCC diagnosed by dynamic CT or magnetic resonance imaging combined with 18F-FDG-PET/CT. The tumor-to-normal liver standardized uptake value ratio (TLR) of the target tumor was measured before treatment using 18F-FDG-PET/CT, with a TLR ≥2 classified as a high potential for malignant HCC. The treatment response was evaluated 2 weeks after the initiation of lenvatinib using modified Response Evaluation Criteria in Solid Tumors. RESULTS: Of the 28 patients, 12 (43%) presented with a TLR ≥2. Evaluation of the treatment response at 2 weeks in these 12 patients revealed that 2 (17%) exhibited a complete response, 8 (67%) a partial response, 2 (17%) stable disease, and none with progressive disease. Therefore, 10 of the 12 patients (83%) experienced an objective response to lenvatinib. On the other hand, 7 of the 16 patients with a TLR

Published
2019

198. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial

Author

Ikeda, Masafumi, Kudo, Masatoshi, Aikata, Hiroshi, Nagamatsu, Hiroaki, Ishii, Hiroshi, Yokosuka, Osamu, Torimura, Takuji, Morimoto, Manabu, Ikeda, Kenji, Kumada, Hiromitsu, Sato, Tosiya, Kawai, Ikuko, Yamashita, Toru, Horio, Hiroshi, Okusaka, Takuji, and Miriplatin TACE Study Group

Subjects
carbohydrates (lipids), Randomized controlled trial, Carcinoma, Miriplatin, polycyclic compounds, Hepatocellular, Chemoembolization, Therapeutic, skin and connective tissue diseases, Epirubicin
Abstract

Background: This prospective study investigated the superiority of transarterial chemoembolization (TACE) with miriplatin over TACE with epirubicin regarding overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC). Methods: Patients with unresectable HCC were randomized 1:1 to receive TACE with miriplatin or epirubicin in lipiodol. The primary endpoint was OS; secondary endpoints were percentages of patients who achieved treatment effect (TE) 4 (100% necrotizing effect or tumor reduction), duration of time to TACE failure, and adverse events (AEs). OS was compared using a stratified log-rank test adjusted for clinical stage, Child–Pugh class, and institution. Results: Of 257 patients enrolled from August 2008 to August 2010, 247 were analyzed for efficacy and toxicity (miriplatin, n = 124; epirubicin, n = 123). Baseline characteristics were well balanced between the two groups. Median OS times were 1111 days for miriplatin and 1127 days for epirubicin (adjusted hazard ratio 1.01, 95% confidence interval 0.73–1.40, P = 0.946). TE4 rates were 44.4% for miriplatin and 37.4% for epirubicin. Median times to TACE failure were 365.5 days for miriplatin and 414.0 days for epirubicin. AEs of grade 3 or higher, including elevated aspartate aminotransferase (miriplatin, 39.5%; epirubicin, 57.7%) and elevated alanine aminotransferase (miriplatin, 31.5%; epirubicin, 53.7%), were less frequent in the miriplatin than the epirubicin group. Conclusions: OS after TACE with miriplatin was not superior to that after TACE with epirubicin; however, hepatic AEs were less frequent with miriplatin.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results